Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AGTR2 | P50052 | 14/20 | 0.62 |
| ▸ | AGTR1 | P30556 | 13/20 | 0.62 |
| ▸ | ABCC3 | O15438 | 1/20 | 0.62 |
| ▸ | ABCC4 | O15439 | 1/20 | 0.62 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.62 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.62 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.62 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.62 |
| ▸ | SLCO1B3 | Q9NPD5 | 1/20 | 0.62 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.62 |
| ▸ | SLCO1B1 | Q9Y6L6 | 1/20 | 0.62 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL669266 | 0.91 | AGTR2 (0.66) | AGTR2AGTR1ABCC3ABCC4ABCB11 | |
| SCHEMBL15132375 | 0.89 | AGTR2 (0.72) | AGTR2AGTR1ABCC3ABCC4ABCB11 | |
| SCHEMBL3841095 | 0.89 | AGTR2 (0.58) | AGTR2AGTR1ABCC3ABCC4ABCB11 | |
| Olmesartan Medoxomil SCHEMBL96150 | 0.88 | AGTR2 (0.79) | AGTR2AGTR1ABCC3ABCC4ABCB11 | |
| SCHEMBL668023 | 0.88 | AGTR2 (0.61) | AGTR2AGTR1ABCC3ABCC4ABCB11 | |
| SCHEMBL29699164 | 0.88 | AGTR1 (0.79) | AGTR2AGTR1ABCC3ABCC4ABCB11 | |
| SCHEMBL3845228 | 0.88 | AGTR2 (0.57) | AGTR2AGTR1ABCC3ABCC4ABCB11 | |
| SCHEMBL1758123 | 0.88 | AGTR2 (0.64) | AGTR2AGTR1ABCC3ABCC4ABCB11 | |
| SCHEMBL6857515 | 0.87 | AGTR2 (0.71) | AGTR2AGTR1ABCC3ABCC4ABCB11 | |
| SCHEMBL2626709 | 0.87 | AGTR2 (0.69) | AGTR2AGTR1ABCC3ABCC4ABCB11 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160102079-A1 | ACETONE SOLVATE CRYSTALS OF TRITYL OMESARTAN MEDOXOMIL | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2016-04-14 | — | — | US | disclosed |
| US-8933241-B2 | Method for producing olmesartan medoxomil | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2015-01-13 | — | — | US | disclosed |
| US-8933241-B2 | Method for producing olmesartan medoxomil | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2015-01-13 | — | — | US | disclosed |
| EP-2426126-B1 | METHOD FOR PRODUCING OLMESARTAN MEDOXOMIL | DAIICHI SANKYO CO LTD (JP) | 2014-11-19 | — | — | EP | disclosed |
| EP-1910343-B1 | PROCESS FOR THE PREPARATION OF OLMESARTAN MEDOXOMIL | KRKA (SI) | 2014-10-29 | — | — | EP | disclosed |
| US-8859600-B2 | Acetone solvate crystals of trityl olmesartan medoxomil | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2014-10-14 | — | — | US | disclosed |
| WO-2012069025-A1 | (5-METHYL-2-OXO-1,3-DIOXOL-4-YLMETHYL)-4-(1-HYDROXY-1-METHYL-PROPYL)-2-PROPYL-1-[2'- (1H-TETRAZOL-5-YL)BIPHENYL-4-YL-METHYL]IMIDAZOLE-5-CARBOXYLATE AS AN IMPURITY OF OLMESARTAN MEDOXOMIL AND A METHOD OF ITS PREPARATION | ZENTIVA, K.S. (CZ) | 2012-05-31 | — | — | WO | disclosed |
| US-20120095237-A1 | Process for the Preparation of 4-(1-Hydroxy-1-Methylethyl)-2-Propyl-Imidazole-5-Carboxylates | SHANGHAI INSTITUTE OF PHARMACEUTICAL INDUSTRY (CN) | 2012-04-19 | — | — | US | disclosed |
| US-20120095237-A1 | Process for the Preparation of 4-(1-Hydroxy-1-Methylethyl)-2-Propyl-Imidazole-5-Carboxylates | SHANGHAI INSTITUTE OF PHARMACEUTICAL INDUSTRY (CN) | 2012-04-19 | — | — | US | disclosed |
| US-20120071665-A1 | METHOD FOR PRODUCING OLMESARTAN MEDOXOMIL | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2012-03-22 | — | — | US | disclosed |
| US-20100076200-A1 | Purification of olmesartan medoxomil | HEDVATI LILACH | 2010-03-25 | — | — | US | disclosed |
| US-20090209603-A1 | Olmesartan medoxomil with reduced levels of impurities | HEDVATI LILACH | 2009-08-20 | — | — | US | disclosed |
| US-20090209603-A1 | Olmesartan medoxomil with reduced levels of impurities | HEDVATI LILACH | 2009-08-20 | — | — | US | disclosed |
| US-7563814-B2 | Olmesartan medoxomil with reduced levels of impurities | TEVA PHARMACEUTICAL INDUSTRIES LTD. (IL) | 2009-07-21 | — | — | US | disclosed |
| US-7563814-B2 | Olmesartan medoxomil with reduced levels of impurities | TEVA PHARMACEUTICAL INDUSTRIES LTD. (IL) | 2009-07-21 | — | — | US | disclosed |
| EP-1816131-A1 | Process for the preparation of olmesartan medoxomil | KRKA, tovarna zdravil, d.d., Novo mesto (SI) | 2007-08-08 | — | — | EP | disclosed |
| US-20070054948-A1 | Purification of olmesartan medoxomil | TEVA PHARMACEUTICALS USA, INC. | 2007-03-08 | — | — | US | disclosed |
| US-20070054948-A1 | Purification of olmesartan medoxomil | TEVA PHARMACEUTICALS USA, INC. | 2007-03-08 | — | — | US | disclosed |
| WO-2007017135-A2 | PROCESS FOR THE PREPARATION OF OLMESARTAN MEDOXOMIL | KRKA (SI) | 2007-02-15 | — | — | WO | disclosed |
| WO-2006029057-A1 | PURIFICATION OF OLMESARTAN MEDOXOMIL | TEVA PHARMACEUTICAL INDUSTRIES, LTD. (IL) | 2006-03-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120071665-A1 | METHOD FOR PRODUCING OLMESARTAN MEDOXOMIL | MSMO1, MTPN, REN | AGTR2 6/4885AGTR1 14/4885ABCC3 4413/4885 |
| US-20160102079-A1 | ACETONE SOLVATE CRYSTALS OF TRITYL OMESARTAN MEDOXOMIL | THOP1, MSMO1, HAAO | AGTR2 29/4885AGTR1 23/4885ABCC3 3412/4885 |
| US-20070054948-A1 | Purification of olmesartan medoxomil | AGTR2, AGTR1, REN | AGTR2 1/4885AGTR1 2/4885ABCC3 3660/4885 |
| US-20100076200-A1 | Purification of olmesartan medoxomil | AGTR2, AGTR1, REN | AGTR2 1/4885AGTR1 2/4885ABCC3 3684/4885 |
| US-20120095237-A1 | Process for the Preparation of 4-(1-Hydroxy-1-Methylethyl)-2-Propyl-Imidazole-5-Carboxylates | MED1, ADH1C, ADH1A | AGTR2 10/4885AGTR1 9/4885ABCC3 4389/4885 |
| US-20090209603-A1 | Olmesartan medoxomil with reduced levels of impurities | O60361, ADRB1, ADRM1 | AGTR2 4/4885AGTR1 5/4885ABCC3 1822/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.